AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Accounts Receivables

Last Annual Value

25.35M

3-Year CAGR

%

5-Year CAGR

132%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Accounts Receivables

SPRY · NASDAQ
CompanyAccounts Receivables
CAGR 3Y
CAGR 5Y
CAGR 10Y
25.35M
N/AN/AN/A 
1.45M
-6.6%10.0%18.1%
SVRA logo
Savara Inc.
NASDAQ:SVRA
0.00
N/AN/AN/A
8.80M
N/AN/A40.4%
0.00
N/AN/AN/A
329.00K
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07